Frazier Life Sciences Management, L.P.: BRIDGEBIO PHARMA INC (BBIO): Quarterly 13F Position History
As of Q1 2026, Frazier Life Sciences Management, L.P. reported 3,448,139 shares of BRIDGEBIO PHARMA INC (BBIO), worth $256.1M and representing 6.6% of its 13F equity book. Quarter-over-quarter share count change: 97,418 (-2.7%) . The position first appeared in Q1 2023 and has been disclosed across 13 13F-HR filings in Pactolio's tracked window.
- 3,448,139Shares Held (Latest Filing)
- $256.1MReported Market Value (Latest Filing)
- 6.6%Portfolio Weight (% of 13F Equity Book)
- 97,418Quarter-over-Quarter Share Change
- -$15.1MQuarter-over-Quarter Value Change
- 3,845,457Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 13 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 3,448,139 | 97,418 | -2.7% | $256.1M | 6.6% | $74.3 |
| Q4 2025 | 3,545,557 | 299,900 | -7.8% | $271.2M | 7.3% | $76.5 |
| Q3 2025 | 3,845,457 | +45,000 | +1.2% | $199.7M | 6.0% | $51.9 |
| Q2 2025 | 3,800,457 | 0 | — | $164.1M | 6.6% | $43.2 |
| Q1 2025 | 3,800,457 | 0 | — | $131.4M | 6.0% | $34.6 |
| Q4 2024 | 3,800,457 | +40,000 | +1.1% | $104.3M | 4.3% | $27.4 |
| Q3 2024 | 3,760,457 | +127,853 | +3.5% | $95.7M | 3.8% | $25.5 |
| Q2 2024 | 3,632,604 | +217,000 | +6.4% | $92.0M | 4.3% | $25.3 |
| Q1 2024 | 3,415,604 | +689,655 | +25.3% | $105.6M | 4.5% | $30.9 |
| Q4 2023 | 2,725,949 | 0 | — | $110.0M | 5.9% | $40.4 |
| Q3 2023 | 2,725,949 | +737,073 | +37.1% | $71.9M | 4.8% | $26.4 |
| Q2 2023 | 1,988,876 | +817,226 | +69.8% | $34.2M | 2.0% | $17.2 |
| Q1 2023 | 1,171,650 | — | — | $19.4M | 1.4% | $16.6 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Frazier Life Sciences Management, L.P. first disclose a BBIO position in 13F-HR filings?
Frazier Life Sciences Management, L.P. first reported BRIDGEBIO PHARMA INC (BBIO) on its 13F-HR filing for the period ending 2023-03-31 (Q1 2023). The position has appeared on 13 reported quarters within Pactolio's tracked window.
What was Frazier Life Sciences Management, L.P.'s most recent quarter-over-quarter share-count change in BBIO?
Between Q4 2025 and Q1 2026, Frazier Life Sciences Management, L.P. reduced its BBIO position by 97,418 shares (-2.7%), leaving 3,448,139 shares at a market value of $256.1M.
Does the implied price-per-share represent Frazier Life Sciences Management, L.P.'s cost basis in BBIO?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.